$SPCX

SpaceX's big week: Stock weathers earnings storm, lock-up expiration in crucial test for investors

SpaceX (SPCX) ended a five-day period up about 2% after its first earnings as a public company and a major lock-up expiration. Q2 results beat estimates, but investors focused on AI capex rising to $15.8B from $7.7B and shares fell 13.6% on Wednesday. On Thursday, 911.5M shares unlocked, doubling public float, yet the stock rose 6.1%.

Original reporting
Published Aug 7, 2026, 1:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 2:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SpaceX's big week: Stock weathers earnings storm, lock-up expiration in crucial test for investors — source image
Decision brief

The 30-second read

$SPCXNeutralMed
01

Why it matters

Traders can treat this week as a two-event stress test: earnings disappointment versus a large, staged share unlock. The stock’s ability to rise on the unlock suggests technical selling may be less than feared, but the article implies the valuation still depends on continued strong execution.

02

Market read

The key tradable takeaway is whether dilution from lock-up expirations will overwhelm fundamentals, and the first tranche’s reaction suggests investors may have already priced much of the supply.

03

What to watch

Subsequent tranches over the coming months could matter more than the first one, especially if AI capex growth continues to pressure margins/valuation.

Relevance 7/10Novelty 6/10Timing: lock-up expiration and post-earnings setup into Friday trading

Background

SpaceX reported its first earnings as a public company and then faced its largest early lock-up expiration tranche, a major test of dilution expectations.

Company-level read

Ticker impact

$SPCXNeutralMedium confidence
Context

SpaceX shares faced Q2 earnings and the first, largest lock-up tranche (911.5M shares eligible), yet the stock closed up 6.1% Thursday.

Expected impact

Near-term downside pressure from dilution appears less severe than feared, but follow-on tranches could still reintroduce technical selling.

Evidence & confidence

It cites a 13.6% drop after Q2 despite the beat, then a 6.1% gain on the first and largest unlock, implying investors had partially priced the dilution.

Market effects

Highlights how IPO-era lock-up mechanics can dominate near-term valuation for high-growth, capital-intensive space/AI-adjacent names.

Limited, primarily affects US-listed SpaceX trading dynamics.

Limited, mostly company-specific supply/demand and investor positioning.

Counterpoint

The unlock outperformance may reflect positioning and expectations already built in, not a durable improvement in fundamentals.

Key entities

  • SpaceX

    Public company whose Q2 results and first, largest lock-up tranche eligibility drove the week’s trading narrative.

  • Nicolas Owens

    Morningstar analyst cited as expecting much of the unlock to sell, but arguing the market had braced.

  • Doug Anmuth

    JPMorgan analyst cited framing the unlock as near-term technical drag.

  • Ron Epstein

    Bank of America analyst cited describing the unlock as technical pressure relief.

Related articles

$SPCXMed

SpaceX Stock Drops 10% as Revenue Beats Expectations

SpaceX shares fell about 10% after its first earnings report as a public company, despite a revenue and adjusted-loss beat, according to Reuters and CNBC. SpaceX reported Q2 revenue of $7.81B (vs est. ~$6.93B) and a net loss of $541M. Investors focused on $18.4B quarterly capex, including $15.83B for AI infrastructure, plus potential post-IPO lock-up selling.

$SPCXMed

SPCX Surges 16%: Lockup Expiration Passes Cleanly

SpaceX (NASDAQ: SPCX) rose 15.8% on Aug. 7, closing at $133.11 after its first post-IPO lockup expiration on Aug. 6 passed without a broad insider selloff. The move followed Q2 results on Aug. 4, when revenue rose 92% to $7.81B. Next unlocks are Aug. 20 and late September.

$SPCXMed

Top Analyst Drops Sharp Take on SpaceX Stock

Argus Research upgraded newly public SpaceX (NASDAQ:SPCX) to Buy from Hold and set a $160 price target. The firm cited Q2 results with revenue up 92% to $7.8B versus $6.93B consensus and a $541M loss, better than expected. Argus expects revenue near $110B in 2027, supporting a ~20x projected-sales valuation amid concerns over rising AI infrastructure spending and share unlocks.

$SPCXMed

SpaceX Stock Surges 10.5% as Argus Sees Rapid AI Payback

Space Exploration Technologies (NASDAQ:SPCX) rose over 12% in Friday trading after Argus upgraded the stock to Buy from Hold and set a $160 price target. Argus cited faster-than-expected AI spending payback. The company reported Q revenue up 92% to $7.81B, adjusted EBITDA up to $3.54B, and AI revenue up 247% to $2.56B, with AI segment profit. Net loss was $541M and AI capex was $15.83B.